Helius Medical Announces Poster to Be Presented at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Conference
May 31 2022 - 08:36AM
Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the
“Company”), a neurotech company focused on neurological wellness,
today announced that an abstract highlighting real-world data,
which shows the impact of translingual neurostimulation as a
rehabilitation therapy to improve gait in people with multiple
sclerosis (MS), has been selected for a poster presentation at the
Consortium for Multiple Sclerosis Centers (CMSC) Annual Meeting
taking place June 1-4 in National Harbor, Maryland.
“We are excited to share our real-world findings on
neuromodulation to improve MS patients’ ability to walk steadily
and safely,” said Antonella Favit-Van Pelt, MD, PhD, Helius
Medical’s Chief Medical Officer. “Our findings show that
neuromodulation stimulation is an effective rehabilitative
intervention that is thought to engage mechanisms of upregulation
and long-term potentiation, promoting neuroplasticity and improving
gait functionality and mobility.”
Poster: Translingual Neurostimulation By Portable
Neuromodulation Stimulator System As a New Rehabilitation Therapy
for Improving Gait in People with Multiple
SclerosisDate: June 2,
2022Presentation Time: 5:00 p.m. - 7:00 p.m.
ETLocation: Prince George’s Exhibit Hall,
Gaylord National Convention Center
Helius Medical representatives will be available to talk about
how neuromodulation can help improve gait for individuals with MS
at Booth #804 in the Exhibit Hall.
Helius Medical is manufacturer of the Portable Neuromodulation
Stimulator (PoNS), an innovative non-surgical medical device,
inclusive of a controller and mouthpiece, which delivers electrical
stimulation to the surface of the tongue to improve balance and
gait. The PoNS device is indicated for use in the United States as
a short-term treatment of gait deficit due to mild-to-moderate
symptoms from MS and is to be used as an adjunct to a supervised
therapeutic exercise program in patients 22 years of age and over
by prescription only. For more information, visit
ponstreatment.com.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in
the medical device field focused on neurologic deficits using
non-implantable platform technologies that amplify the brain’s
ability to compensate and promotes neuroplasticity, aiming to
improve the lives of people dealing with neurologic diseases. The
Company’s first commercial product is the Portable Neuromodulation
Stimulator (PoNS). For more information,
visit www.heliusmedical.com.
Contact:
Patty Caballero862.216.7523patty@pscconsulting.net
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Mar 2023 to Mar 2024